Relay Therapeutics (RLAY) Cash & Equivalents (2020 - 2025)
Historic Cash & Equivalents for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $91.6 million.
- Relay Therapeutics' Cash & Equivalents fell 3990.17% to $91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year decrease of 3990.17%. This contributed to the annual value of $124.3 million for FY2024, which is 1353.11% down from last year.
- Relay Therapeutics' Cash & Equivalents amounted to $91.6 million in Q3 2025, which was down 3990.17% from $113.9 million recorded in Q2 2025.
- Relay Therapeutics' Cash & Equivalents' 5-year high stood at $354.6 million during Q3 2022, with a 5-year trough of $91.6 million in Q3 2025.
- Over the past 5 years, Relay Therapeutics' median Cash & Equivalents value was $151.3 million (recorded in 2023), while the average stood at $170.0 million.
- The largest annual percentage gain for Relay Therapeutics' Cash & Equivalents in the last 5 years was 27348.95% (2021), contrasted with its biggest fall of 5913.35% (2021).
- Relay Therapeutics' Cash & Equivalents (Quarter) stood at $280.1 million in 2021, then plummeted by 45.81% to $151.8 million in 2022, then dropped by 5.31% to $143.7 million in 2023, then decreased by 13.53% to $124.3 million in 2024, then dropped by 26.33% to $91.6 million in 2025.
- Its last three reported values are $91.6 million in Q3 2025, $113.9 million for Q2 2025, and $93.5 million during Q1 2025.